首页 › 基金 › ORBIMED ADVISORS LLC › SPRY
ORBIMED ADVISORS LLC 对 SPRY 的持仓历史
ARS PHARMACEUTICALS INC · 医疗保健
ORBIMED ADVISORS LLC 在 Q2 2026 的 13F 申报中披露持有 SPRY(ARS PHARMACEUTICALS INC)8,288,510 股,市值约 US$66.4M,约占其申报组合的 1.33%,在其申报持仓中市值排名第 20 位。 ORBIMED ADVISORS LLC 最近 12 个申报季度中有 12 个季度披露了 SPRY 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
ORBIMED ADVISORS LLC 对 SPRY 的持仓演变
ORBIMED ADVISORS LLC 于 Q3 2023 首次披露 SPRY 持仓:9,240,887 股(约 US$34.9M)。 该持仓在 Q2 2025 达到峰值 8,288,510 股,市值约 US$144.6M。 在 12 次申报中,ORBIMED ADVISORS LLC 0 次增持、1 次减持、10 次保持不变。 最近一期申报(Q2 2026)显示持股 8,288,510 股、市值约 US$66.4M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 9.24M | $34.93M | 新进 |
| Q4 2023 | 9.24M | $50.64M | 持有 |
| Q1 2024 | 9.24M | $94.44M | 持有 |
| Q2 2024 | 9.24M | $78.64M | 持有 |
| Q3 2024 | 8.29M | $120.18M | 减持 |
| Q4 2024 | 8.29M | $87.44M | 持有 |
| Q1 2025 | 8.29M | $104.27M | 持有 |
| Q2 2025 | 8.29M | $144.63M | 持有 |
| Q3 2025 | 8.29M | $83.30M | 持有 |
| Q4 2025 | 8.29M | $96.56M | 持有 |
| Q1 2026 | 8.29M | $66.56M | 持有 |
| Q2 2026 | 8.29M | $66.39M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 SPRY 与 13F 数据
SPRY(ARS PHARMACEUTICALS INC)属于医疗保健行业。我们追踪的基金中还有 24 只申报持有 SPRY,申报仓位最大的包括:RA CAPITAL MANAGEMENT, L.P. (US$87.0M), Rubric Capital Management LP (US$68.4M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$60.1M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 SPRY 的基金
- RA CAPITAL MANAGEMENT, L.P. 10.86M 股 · $87.00M · Q2 2026
- Rubric Capital Management LP 8.54M 股 · $68.41M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 7.50M 股 · $60.11M · Q2 2026
- Tyro Capital Management LLC 4.46M 股 · $35.72M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 4.01M 股 · $32.14M · Q2 2026
- GENERAL AMERICAN INVESTORS CO INC 1.13M 股 · $9.08M · Q2 2026
- Third Point 1.00M 股 · $8.01M · Q2 2026
- Third Point LLC 1.00M 股 · $8.01M · Q2 2026
- Tejara Capital Ltd 607.04K 股 · $4.86M · Q2 2026
更多关于 ORBIMED ADVISORS LLC
常见问题
How long has ORBIMED ADVISORS LLC held SPRY?
ORBIMED ADVISORS LLC has disclosed SPRY holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is ORBIMED ADVISORS LLC's current position in SPRY?
As of Q2 2026, ORBIMED ADVISORS LLC holds 8.29M shares of SPRY (ARS PHARMACEUTICALS INC), valued at $66.39M, representing 1.33% of its reported portfolio and ranking #20.
Has ORBIMED ADVISORS LLC been buying or selling SPRY?
In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC held unchanged its position in SPRY. The position peaked in Q2 2025 at 8.29M shares.
Which other funds hold SPRY?
Other major institutional holders of SPRY include RA CAPITAL MANAGEMENT, L.P., Rubric Capital Management LP, DEERFIELD MANAGEMENT COMPANY, L.P., among 24 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.